Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Burtscher D, Van der Bergh R, Toktosunov U, Angmo N, Samieva N, et al.
2016-03-28 • PLOS One
2016-03-28 • PLOS One
Kyrgyzstan is one of the 27 high multidrug-resistant tuberculosis (MDR-TB) burden countries listed by the WHO. In 2012, Médecins Sans Frontières (MSF) started a drug-resistant tuberculos...
Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N, et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
BACKGROUND At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...
Goncharova O, Denisiuk O, Zachariah R, Davtyan K, Nabirova D, et al.
2017-09-01 • Public Health Action
2017-09-01 • Public Health Action
Setting: Twenty-two first-line, two second-line and one tertiary health facility in Bishkek, the capital of Kyrgyzstan. Objectives: Among migrants, a marginalised population at risk for ...
The World Health Organization (WHO) currently recommends Xpert® MTB/RIF as the initial test for all people with presumptive tuberculosis (TB). A number of challenges have been reported, ...
Bastard M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, Khurkhumal S, et al.
2019-10-01 • International Journal of Tuberculosis and Lung Disease
2019-10-01 • International Journal of Tuberculosis and Lung Disease
INTRODUCTION Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....
Kulzhabaeva A, Nabirova D, Usenbaev N, Denisiuk O, Zachariah R
2016-03-01 • Public Health Panorama
2016-03-01 • Public Health Panorama
The performance of the tuberculosis (TB) programme should be judged on the basis of detected TB cases recorded in the laboratory register and not just those placed on treatment and recor...
